Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)

The summary for the Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional): The overall goal of this initiative is to identify neurophysiological measures potential assays for treatment development research. The funding opportunity announcement (FOA) will support efforts to optimize and evaluate measures of neurophysiological processes that are disrupted within or across mental disorders in both healthy humans and in another species relevant to the therapeutic development pipeline. The initiative will support initial proof of concept studies aimed at identifying measures for potential development as preclinical assays for evaluating potential new drug and device therapies and their targets. Data will also reveal assay measures where the performance between preclinical animal species and humans is dissimilar, thus establishing a firm basis for limiting speculative extrapolations of preclinical animal findings to humans. The ultimate practical goal of this FOA is to improve the efficiency of the therapeutic development process by identifying coherence of measures and inconsistencies between the preclinical screening pipeline and clinical evaluation of new treatment candidates and thereby hasten the development of more effective treatments for mental disorders.
Federal Grant Title: Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)
Federal Agency Name: National Institutes of Health (HHS-NIH11)
Grant Categories: Health
Type of Opportunity: Discretionary
Funding Opportunity Number: PAR-19-214
Type of Funding: Cooperative Agreement
CFDA Numbers: 93.242
CFDA Descriptions: Information not provided
Current Application Deadline: February 21st, 2022
Original Application Deadline: February 21st, 2022
Posted Date: March 8th, 2019
Creation Date: March 8th, 2019
Archive Date: March 29th, 2022
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Last Updated: March 8th, 2019
Applicants Eligible for this Grant
State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement
http://grants.nih.gov/grants/guide/pa-files/PAR-19-214.html
Grant Announcement Contact
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants
Explainable Artificial Intelligence for Decoding and Modulating Neural Circuit Activity Li...
Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle-Inco...
Computational Methods for Integrating Tissue and Single Cell Genomic Data from the Brain (...
Non-Invasive Neurostimulation in AD/ADRD (R01 Clinical Trial Optional)
Limited Competition: Continuation of the Center for Genomic Studies on Mental Disorders (U...
Development of Biomarkers for Mental Health Research and Clinical Utilities: (STTR [R41/R4...
Development of Biomarkers for Mental Health Research and Clinical Utilities (SBIR [R43/R44...
Pharmacologic Agents and Drugs for Mental Disorders (SBIR [R43/R44])
More Grants from the National Institutes of Health
Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R...
Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R...
Investigations on Primary Immunodeficiency Diseases/Inborn Errors of Immunity (R03 Clinica...
NIDA Program Project Grant Applications (P01 Clinical Trial Optional)
NCI Outstanding Investigator Award (R35 Clinical Trial Not Allowed)

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2019 FederalGrants.com